High-resolution genome-wide copy-number analyses identify localized copy-number alterations in Ewing sarcoma

Diagnostic Molecular Pathology

Volumn 22, Issue 2, 2013, Pages 76-84

  Lynn, Miriam ^a   Wang, Yuexiang ^f   Slater, Jaime ^f   Shah, Naisha ^d   Conroy, Judith ^d   Ennis, Sean ^d   Morris, Thomas ^b   Betts, David R ^b   Fletcher, Jonathan A ^f   O'Sullivan, Maureen J ^a,c,e  

^a NATIONAL CHILDREN S RESEARCH CENTRE   (Ireland)

^b National Centre for Medical Genetics   (Ireland)

^c OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

^e TRINITY COLLEGE DUBLIN   (Ireland)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Copy number alteration; Ewing sarcoma; Genome wide copy number analysis; Peripheral primitive neuroectodermal tumor

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR SOX6;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHROMOSOME 10Q; CHROMOSOME 11P; CHROMOSOME 17P; CHROMOSOME 1Q; CHROMOSOME 8; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER ALTERATION; EWING SARCOMA; FEMALE; GENE DOSAGE; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 8; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA COPY NUMBER VARIATIONS; FEMALE; GENE DELETION; GENOME-WIDE ASSOCIATION STUDY; HETEROZYGOTE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PTEN PHOSPHOHYDROLASE; REPRODUCIBILITY OF RESULTS; SARCOMA, EWING; SOXD TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84879936495     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31827a47f9     Document Type: Article

References (41)

1. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999;341:342-352.
2. Turc-Carel C, Aurias A, Mugneret F, et al. Chromosomes in Ewing's sarcoma. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet. 1988;32:229-238.
3. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359:162-165.
4. Braunreiter CL, Hancock JD, Coffin CM, et al. Expression of EWSETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma. Cell Cycle. 2006;5:2753-2759.
5. May WA, Gishizky ML, Lessnick SL, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci USA. 1993;90:5752-5756.
6. Joo J, Christensen L, Warner K, et al. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. PLoS One. 2009;4:e7608.
7. Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res. 2006;4:851-859.
8. Smith R, Owen LA, Trem DJ, et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell. 2006;9:405-416.
9. Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETSfamily transcription factor, ERG. Nat Genet. 1994;6:146-151.
10. Jeon IS, Davis JN, Braun BS, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene. 1995;10:1229-1234.
11. Kaneko Y, Yoshida K, Handa M, et al. Fusion of an ETS-family gene, EIAF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. Genes Chromosomes Cancer. 1996;15:115-121.
12. Peter M, Couturier J, Pacquement H, et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene. 1997;14: 1159-1164.
13. Shing DC, McMullan DJ, Roberts P, et al. FUS/ERG gene fusions in Ewing's tumors. Cancer Res. 2003;63:4568-4576.
14. Ng TL, O'Sullivan MJ, Pallen CJ, et al. Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. J Mol Diagn. 2007;9:459-463.
15. Teitell MA, Thompson AD, Sorensen PH, et al. EWS/ETS fusion genes induce epithelial and neuroectodermal differentiation in NIH 3T3 fibroblasts. Lab Invest. 1999;79:1535-1543.
16. Thompson AD, Teitell MA, Arvand A, et al. Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells. Oncogene. 1999;18:5506-5513.
17. Le Deley MC, Delattre O, Schaefer KL, et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol. 2010;28:1982-1988.
18. van Doorninck JA, Ji L, Schaub B, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2010;28:1989-1994.
19. Ferreira BI, Alonso J, Carrillo J, et al. Array CGH and geneexpression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing's sarcoma. Oncogene. 2008;27:2084-2090.
20. Savola S, Klami A, Tripathi A, et al. Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer. 2009;9:17-30.
21. Roberts P, Burchill SA, Brownhill S, et al. Ploidy and karyotype complexity are powerful prognostic indicators in the Ewing's sarcoma family of tumors: a study by the United Kingdom Cancer Cytogenetics and the Children's Cancer and Leukaemia Group. Genes Chromosomes Cancer. 2008;47:207-220.
22. Park YK, Chi SG, Kim YW, et al. P53 mutations in Ewing's sarcoma. Oncol Rep. 2001;8:533-537.
23. Tsuchiya T, Sekine K, Hinohara S, et al. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet. 2000;120:91-98.
24. Wei G, Antonescu CR, de Alava E, et al. Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer. 2000;89:793-799.
25. Wang K, Li M, Hadley D, et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 2007;17:1665-1674.
26. Verselis SJ, Rheinwald JG, Fraumeni JF Jr, et al. Novel p53 splice site mutations in three families with Li-Fraumeni syndrome. Oncogene. 2000;19:4230-4235.
27. Iafrate AJ, Feuk L, Rivera MN, et al. Detection of large-scale variation in the human genome. Nat Genet. 2004;36:949-951.
28. Pazzaglia L, Chiechi A, Conti A, et al. Genetic and molecular alterations in rhabdomyosarcoma: mRNA overexpression of MCL1 and MAP2K4 genes. Histol Histopathol. 2009;24:61-67.
29. Moritake H, Sugimoto T, Kuroda H, et al. Newly established Askin tumor cell line and overexpression of focal adhesion kinase in Ewing sarcoma family of tumors cell lines. Cancer Genet Cytogenet. 2003;146:102-109.
30. Cao L, Yu Y, Bilke S, et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res. 2010;70: 6497-6508.
31. Bouron-Dal Soglio D, Rougemont AL, Absi R, et al. SNP genotyping of a sclerosing rhabdomyosarcoma: reveals highly aneuploid profile and a specific MDM2/HMGA2 amplification. Hum Pathol. 2009;40:1347-1352.
32. Ladanyi M, Lewis R, Jhanwar SC, et al. MDM2 and CDK4 gene amplification in Ewing's sarcoma. J Pathol. 1995;175:211-217.
33. Neale G, Su X, Morton CL, et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res. 2008;14: 4572-4583.
34. Squire JA, Pei J, Marrano P, et al. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer. 2003;38:215-225.
35. Ozaki T, Paulussen M, Poremba C, et al. Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors. Genes Chromosomes Cancer. 2001;32:164-171.
36. Armengol G, Tarkkanen M, Virolainen M, et al. Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br J Cancer. 1997;75:1403-1409.
37. Brisset S, Schleiermacher G, Peter M, et al. CGH analysis of secondary genetic changes in Ewing tumors: correlation with metastatic disease in a series of 43 cases. Cancer Genet Cytogenet. 2001;130:57-61.
38. Hattinger CM, Potschger U, Tarkkanen M, et al. Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer. 2002;86:1763-1769.
39. Maurici D, Perez-Atayde A, Grier HE, et al. Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma. Cancer Genet Cytogenet. 1998;100:106-110.
40. Li Y, Tanaka K, Fan X, et al. Inhibition of the transcriptional function of p53 by EWS-Fli1 chimeric protein in Ewing Family Tumors. Cancer Lett. 2010;294:57-65.
41. Steigen SE, Schaeffer DF, West RB, et al. Expression of insulin-like growth factor 2 in mesenchymal neoplasms. Mod Pathol. 2009;22: 914-921.